- Myotubular Myopathy
- Autosomal Centronuclear Myopathies
- Others
Centronuclear Myopathy Market size was valued at USD XX million in 2022 and is poised to grow at a CAGR of XX% over 2023-2029. Centronuclear myopathies (CNM) are a group of congenital myopathies, that occur mainly because of mutation in the MTM1 gene, where cell nuclei are abnormally located in the center of muscle cells instead of their normal location at the periphery, symptoms include severe hypotonia, hypoxia requiring breathing assistance, and scaphocephaly. As per a research report, the X-liked form of centronuclear myopathy has an incidence rate of 1 per 50,000 male births. The rise in the demand and need for novel therapeutics will act as the growth driver for the market. However, the limited availability of medicinal treatment options due to the low prevalence of centronuclear myopathy is the factor hindering the market growth. Financial support from the government and an increase in strategic collaborations between the market players are huge growth opportunities for the expansion of the market.
Centronuclear Myopathy Market Key Developments:
- In Nov 2021, Dynacure and Nippon Shinyaku entered into a long-term strategic development and commercialization agreement for Dynacure’s DYN-101, for the treatment of centronuclear myopathies.
- In Jan 2023, ARMGO Pharma’s ARM 210 was in phase-I development for congenital structural myopathies in the USA.
Centronuclear Myopathy Market Summary
Study Period
2023-29
Base Year
N/A
CAGR
x%
Largest Market
North America
Fastest Growing Market
North America
Centronuclear Myopathy Market Dynamics
Companies and academics are working to assess challenges and seek opportunities that could influence CNM research and development, primarily focusing on novel approaches. Furthermore, the emerging therapies for centronuclear myopathies such as ARM210, DYN101, and AT-132, which are currently in the clinical investigation phases will participate in the growth of the market. Thus, the increased awareness, research, and development for centronuclear myopathy will lead to the growth of the market within the forecast period, whereas, fewer approvals of drugs from the regulatory authorities could pose as restraining factor in the market growth.
North-America Got Significant Share of
Centronuclear Myopathy Market Regional Analysis
The Centronuclear Myopathy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to the National Organization for Rare Disorders, more than 100 families have been reported to have DNM2-related CNM, and both B1N1-related CNM and RYR1-related CNM have been reported in fewer than 50 individuals. The North America Centronuclear Myopathy market is expected to dominate the market over the forecast period, majorly because of the highly developed healthcare systems in the United States and Canada, as well as the strong presence of major market players, and the rising prevalence of the disease in the region. Additionally, Asia Pacific region is also expected to witness significant growth in the Centronuclear Myopathy market owing to the increasing number of market players in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The centronuclear myopathy market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Centronuclear Myopathy Market Segmentation
By Type
By Treatment Type
- Night-time Ventilation
- Gastrostomy
- Physiotherapy
- Antibiotics
- Others
By Diagnosis
- Muscle Biopsy
- Molecular Testing
- Others
By End User
- Hospitals
- Clinics
- Homecare
- Others
Frequently Asked Questions
The Centronuclear Myopathy market was valued at USD XX million in 2022 and is expected to grow at a XX% CAGR over the forecast period 2023 – 2029.
Financial support from the government and an increase in strategic collaborations between the market players are the key opportunities for the Centronuclear Myopathy market.
The rise in the demand and need for novel therapeutics is the driver in the Centronuclear Myopathy market.
Audentes Therapeutics, Ionis Pharmaceuticals, Inc., Dynacure, Valerion Therapeutics, Biophytis, ARMGO Pharma Inc., Stealth BioTherapeutics Inc., Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., and GlaxoSmithKline plc. are a few companies operating in the Centronuclear Myopathy market.
- Audentes Therapeutics
- Ionis Pharmaceuticals, Inc.
- Dynacure
- Valerion Therapeutics
- Biophytis
- ARMGO Pharma Inc.
- Stealth BioTherapeutics Inc.
- Novartis AG
- CENTOGENE AG
- Sanofi
- KalVista Pharmaceuticals
- Pfizer Inc.
- GlaxoSmithKline plc.
- AstraZeneca
- Medtronic
- Roche Ltd,
- Amgen Inc.